Literature DB >> 15243035

Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl).

Ulrich Vogel1, Heike Claus, Lutz von Müller, Donald Bunjes, Johannes Elias, Matthias Frosch.   

Abstract

We recently described the capsule null locus (cnl) of constitutively unencapsulated Neisseria meningitidis clonal lineages. cnl meningococci were recovered from healthy carriers at high frequency. We here report on the first case of invasive disease caused by cnl meningococci in a severely immunosuppressed patient with chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. The sequence type 845 strain was extensively typed and, furthermore, shown to be sensitive to serum bactericidal activity.

Entities:  

Mesh:

Year:  2004        PMID: 15243035      PMCID: PMC446252          DOI: 10.1128/JCM.42.7.2898-2901.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Nosocomial meningococcemia in a physician.

Authors:  J F Gehanno; L Kohen-Couderc; J F Lemeland; J Leroy
Journal:  Infect Control Hosp Epidemiol       Date:  1999-08       Impact factor: 3.254

Review 2.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

3.  Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients.

Authors:  T Parkkali; H Käyhty; H Lehtonen; T Ruutu; L Volin; J Eskola; P Ruutu
Journal:  Bone Marrow Transplant       Date:  2001-01       Impact factor: 5.483

4.  Waldenström's disease complicated by recurrent meningococcal arthritis.

Authors:  M Singwe-Ngandeu; N Buchs; P Rohner; C Gabay
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

5.  Neisseria meningitidis serogroup 29E (Z') septicemia in a patient with far advanced multiple myeloma (plasma cell leukemia).

Authors:  E Wachter; A E Brown; T E Kiehn; B J Lee; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

6.  Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component.

Authors:  Emily A L Thompson; Ian M Feavers; Martin C J Maiden
Journal:  Microbiology       Date:  2003-07       Impact factor: 2.777

7.  Many carried meningococci lack the genes required for capsule synthesis and transport.

Authors:  Heike Claus; Martin C J Maiden; Rainer Maag; Matthias Frosch; Ulrich Vogel
Journal:  Microbiology       Date:  2002-06       Impact factor: 2.777

8.  Meningococcemia caused by serogroup W135. Association with hypogammaglobulinemia.

Authors:  I E Salit
Journal:  Arch Intern Med       Date:  1981-04

9.  Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity.

Authors:  Sanjay Ram; Andrew D Cox; J Claire Wright; Ulrich Vogel; Silke Getzlaff; Ryan Boden; Jianjun Li; Joyce S Plested; Seppo Meri; Sunita Gulati; Daniel C Stein; James C Richards; E Richard Moxon; Peter A Rice
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

10.  Carried meningococci in the Czech Republic: a diverse recombining population.

Authors:  K A Jolley; J Kalmusova; E J Feil; S Gupta; M Musilek; P Kriz; M C Maiden
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

View more
  23 in total

Review 1.  Biofilm formation by the human pathogen Neisseria meningitidis.

Authors:  Martin Lappann; Ulrich Vogel
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 3.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

Review 4.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

5.  Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis.

Authors:  Kay O Johswich; Jianwei Zhou; Dennis K S Law; Frank St Michael; Shannon E McCaw; Frances B Jamieson; Andrew D Cox; Raymond S W Tsang; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2012-04-16       Impact factor: 3.441

6.  Genome sequence of a Neisseria meningitidis capsule null locus strain from the clonal complex of sequence type 198.

Authors:  Sabine Schork; Andreas Schlüter; Jochen Blom; Susanne Schneiker-Bekel; Alfred Pühler; Alexander Goesmann; Matthias Frosch; Christoph Schoen
Journal:  J Bacteriol       Date:  2012-09       Impact factor: 3.490

7.  Genotypic and Phenotypic Characterization of the O-Linked Protein Glycosylation System Reveals High Glycan Diversity in Paired Meningococcal Carriage Isolates.

Authors:  Bente Børud; Guro K Bårnes; Ola Brønstad Brynildsrud; Elisabeth Fritzsønn; Dominique A Caugant
Journal:  J Bacteriol       Date:  2018-07-25       Impact factor: 3.490

8.  Consecutive use of two multiplex PCR-based assays for simultaneous identification and determination of capsular status of nine common Neisseria meningitidis serogroups associated with invasive disease.

Authors:  Désirée E Bennett; Mary T Cafferkey
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 9.  Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.

Authors:  Elisabeth Kugelberg; Bridget Gollan; Christoph M Tang
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 10.  Meningococcal carriage and disease--population biology and evolution.

Authors:  Dominique A Caugant; Martin C J Maiden
Journal:  Vaccine       Date:  2009-05-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.